Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 55.90
-0.20 (-0.36%)
Dec 3, 2025, 1:35 PM CST
Tanvex BioPharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -1,358 | -1,382 | -2,137 | -1,641 | -1,543 | -2,104 | Upgrade |
Depreciation & Amortization | 350.59 | 287.56 | 323.59 | 280.01 | 241.43 | 215.83 | Upgrade |
Other Amortization | 1.48 | 1.48 | 1.24 | 1.55 | 2.15 | 4.58 | Upgrade |
Loss (Gain) From Sale of Assets | -15.21 | -0.08 | 2.87 | 7.21 | 0.94 | 0.27 | Upgrade |
Asset Writedown & Restructuring Costs | 49.19 | - | 8.67 | - | - | - | Upgrade |
Stock-Based Compensation | 5.26 | -2.16 | 326.61 | 67.55 | 52.95 | 80.36 | Upgrade |
Other Operating Activities | -2.31 | 17.88 | -1.23 | - | -90.2 | 0.63 | Upgrade |
Change in Accounts Receivable | 161.7 | 9.33 | -9.06 | 2.19 | -2.52 | -0.72 | Upgrade |
Change in Inventory | -228.09 | -109.55 | 62.56 | -80.51 | -40.25 | 2.12 | Upgrade |
Change in Accounts Payable | 41.25 | 1.75 | 33.41 | -15.59 | -66.97 | 32.43 | Upgrade |
Change in Unearned Revenue | -44.77 | -0.56 | -10.93 | 28.07 | - | - | Upgrade |
Change in Other Net Operating Assets | -78.58 | 25.3 | -35.98 | 16.82 | 58.67 | -18.88 | Upgrade |
Operating Cash Flow | -1,123 | -1,151 | -1,435 | -1,334 | -1,387 | -1,788 | Upgrade |
Capital Expenditures | -232.06 | -105.91 | -71.02 | -93.5 | -29.82 | -66.03 | Upgrade |
Sale of Property, Plant & Equipment | 11.73 | 0.14 | 6.33 | 1.82 | 6.7 | 0.17 | Upgrade |
Sale (Purchase) of Intangibles | -4.01 | -4.86 | -0.32 | -2.58 | -0.52 | -1.47 | Upgrade |
Investment in Securities | 5 | - | - | - | - | -193.87 | Upgrade |
Other Investing Activities | -175.01 | 1.38 | -18.57 | -3.09 | -1.04 | 17.9 | Upgrade |
Investing Cash Flow | 609.92 | -109.25 | -83.57 | -97.35 | -24.68 | -243.3 | Upgrade |
Short-Term Debt Issued | - | 377.65 | - | - | - | - | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 94.87 | Upgrade |
Total Debt Issued | - | 377.65 | - | - | - | 94.87 | Upgrade |
Short-Term Debt Repaid | - | -377.65 | - | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -184.58 | -127.67 | -130.53 | -93.11 | -67.76 | Upgrade |
Total Debt Repaid | -176.03 | -562.23 | -127.67 | -130.53 | -93.11 | -67.76 | Upgrade |
Net Debt Issued (Repaid) | -176.03 | -184.58 | -127.67 | -130.53 | -93.11 | 27.11 | Upgrade |
Issuance of Common Stock | 1,263 | 1,440 | 1,207 | 7.24 | 1,690 | 1,703 | Upgrade |
Other Financing Activities | 0.22 | - | - | - | - | - | Upgrade |
Financing Cash Flow | 1,087 | 1,255 | 1,080 | -123.29 | 1,597 | 1,730 | Upgrade |
Foreign Exchange Rate Adjustments | 77.13 | 0.98 | 33.91 | 117.75 | -31.25 | -58.41 | Upgrade |
Net Cash Flow | 650.95 | -3.79 | -405.48 | -1,437 | 154.37 | -358.84 | Upgrade |
Free Cash Flow | -1,355 | -1,257 | -1,506 | -1,427 | -1,417 | -1,854 | Upgrade |
Free Cash Flow Margin | -602.79% | -3623.36% | -2452.94% | -6370.97% | -26208.75% | -617884.67% | Upgrade |
Free Cash Flow Per Share | -6.16 | -8.09 | -11.69 | -12.14 | -13.05 | -20.71 | Upgrade |
Cash Interest Paid | 48.4 | 53.34 | 57.38 | 54.72 | 45.81 | 17.96 | Upgrade |
Cash Income Tax Paid | 1.18 | 1.02 | 0.88 | 0.02 | 0.02 | 0.02 | Upgrade |
Levered Free Cash Flow | -858.15 | -792.54 | -713.06 | -844.23 | -819.13 | -1,075 | Upgrade |
Unlevered Free Cash Flow | -827.91 | -759.2 | -677.19 | -810.03 | -790.24 | -1,063 | Upgrade |
Change in Working Capital | -148.49 | -73.73 | 39.99 | -49.03 | -51.08 | 14.94 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.